Based on the key indicators related to Cardio Diagnostics' liquidity, profitability, solvency, and operating efficiency, Cardio Diagnostics Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Cardio Diagnostics' Other Current Liabilities is fairly stable compared to the past year. Accounts Payable is likely to climb to about 389.2 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 580.3 K in 2024. Key indicators impacting Cardio Diagnostics' financial strength include:
Investors should never underestimate Cardio Diagnostics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cardio Diagnostics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Cardio Diagnostics Holdings.
Net Income
(7.96 Million)
Cardio
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Capital Stock
Net Working Capital
Intangible Assets
Common Stock
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Probability Of Bankruptcy
Understanding current and past Cardio Diagnostics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cardio Diagnostics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cardio Diagnostics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Cardio Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardio Diagnostics Holdings. Check Cardio Diagnostics' Beneish M Score to see the likelihood of Cardio Diagnostics' management manipulating its earnings.
Cardio Diagnostics Stock Summary
Cardio Diagnostics competes with Cardio Diagnostics, and OmniAb. Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Cardio Diagnostics's current stock value. Our valuation model uses many indicators to compare Cardio Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardio Diagnostics competition to find correlations between indicators driving Cardio Diagnostics's intrinsic value. More Info.
Cardio Diagnostics Holdings is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At this time, Cardio Diagnostics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardio Diagnostics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Cardio Diagnostics Systematic Risk
Cardio Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cardio Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Cardio Diagnostics correlated with the market. If Beta is less than 0 Cardio Diagnostics generally moves in the opposite direction as compared to the market. If Cardio Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cardio Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cardio Diagnostics is generally in the same direction as the market. If Beta > 1 Cardio Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Cardio Diagnostics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Cardio has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Cardio Diagnostics' financials are consistent with your investment objective using the following steps:
Review Cardio Diagnostics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Cardio Diagnostics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Cardio Diagnostics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Cardio Diagnostics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Cardio Diagnostics Thematic Clasifications
Cardio Diagnostics Holdings is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Cardio Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cardio Diagnostics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cardio Diagnostics growth as a starting point in their analysis.
Cardio Diagnostics November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cardio Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cardio Diagnostics Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cardio Diagnostics Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Cardio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cardio Diagnostics's daily price indicators and compare them against related drivers.
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.